期刊
CHEMISTRY-A EUROPEAN JOURNAL
卷 26, 期 63, 页码 14335-14340出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.202002963
关键词
bimodal therapy; boron neutron capture therapy; carboranes; glioblastoma; sunitinib
资金
- FCE-ANII [FCE_3_2018_1_148288]
- CSIC-Universidad de la Republica (UdelaR) (Grupo I+D) [CSIC-421]
- ANII [POS_NAC_2015_1_110068]
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than(10)B-boronophenylalanine fructose complex when the cells were irradiated with neutrons.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据